Aptar Pharma provides unit-dose nasal spray technology for the treatment of opioid overdose
Image - Narcan Adapt Pharma - Courtesy of Adapt Pharma.
The delivery system is for Adept Pharma's Narcan - the first FDA-approved nasally administered, needle-free, ready-to use medication that can stop or reverse the effects of an opioid overdose.
Aptar Pharma has provided the delivery system and regulatory support for Adapt Pharma’s Narcan, which is the first FDA-approved nasally administered, needle-free, ready-to use medication that can stop or reverse the effects of an opioid overdose.
Narcan contains naloxone, which is an opioid antagonist. It is marketed in the US for emergency treatment of known or suspected opioid overdose. “The US is facing an unprecedented opioid overdose epidemic. By making Narcan Nasal Spray available, we hope to increase everyone’s access to emergency treatments across the US,” said Seamus Mulligan, Chairman and CEO of Adapt Pharma.
Aptar Pharma has brought to the partnership its unique experience in nasal drug delivery and regulatory expertise in relation to combination drug-device products successfully supporting Adapt Pharma’s new drug application.
“Aptar Pharma leads the industry in nasal drug delivery expertise. We have collaborated closely with Adapt Pharma to ensure the rapid approval of this potentially life-saving product using our Unit-Dose System (UDS). The regulations and requirements for market approvals are rapidly evolving and customers must seek out trusted partners like Aptar Pharma. We are continually investing in resources and capabilities to support our customers in reaching the market quickly,” said Salim Haffar, President of Aptar Pharma.
Estimated at over $2 billion in 2015, the world market for intra-nasal spray systemic drug delivery has experienced strong growth in the last few years. The list of therapies successfully treated via the nasal route continues to grow from the traditional areas of migraine, osteoporosis and endometriosis, to now include: post-operative pain (ketorolac), cancer pain (fentanyl), osteoporosis, prostate cancer, urinary incontinence, anemia and vaccinations.
Aptar Pharma’s UDS is the preferred liquid spray drug delivery technology platform when dose accuracy and ease of administration are critical. The single-shot UDS system’s primeless feature combined with 360° orientation offer the patient or the caregiver unique ready-to-use convenience.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.